LRP6 and Hypertension: Mani et al. found a missense mutation (R611C) in LRP6, which substitutes cysteine for arginine at highly conserved residue of an EGF-like domain and impairs Wnt signaling in vitro, contributes to the metabolic syndrome including early coronary artery disease, hyperlipidemia, hypertension, and diabetes (13).